Live Breaking News & Updates on First In Class Peptide

Stay updated with breaking news from First in class peptide. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Grants Orphan Drug Designation to '1104, First-In-Class Peptide for Eosinophilic Esophagitis

The designation offers support in developing potential new medicines, treatment, and diagnosis to prevent rare conditions, like EoE. ....

United States , Evan Dellon , Revolo Biotherapeutics , University Of North Carolina Chapel Hill , Orphan Drug Designation , Adjunct Professor , North Carolina Chapel Hill , Principal Investigator , Woody Bryan , Chief Executive Officer , First In Class Peptide , Potential Treatment , Dev Landscape , Active Eosinophilic ,

Revolo Biotherapeutics to Host Virtual KOL Event on '1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease

Revolo Biotherapeutics to Host Virtual KOL Event on '1104: A First-in-Class Peptide for Eosinophilic Esophagitis (EoE) and Allergic Disease
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

City Of , United Kingdom , United States , Evans Dellon , Revolo Biotherapeutics , Revolo Biotherapeutic , Marylyn Rigby , Mohamed Shamji , Evan Dellon , Revolo Bio , Monica Rouco Molina , Lifesci Communications , University Of North Carolina School Medicine , National Heart Lung Institute , Masters Of Public Health , Imperial College London , Company Contact , Clinical Immunology At Imperial College London , Johns Hopkins School Of Medicine , Brown University , School Of Public Health , Host Virtual , First In Class Peptide , Eosinophilic Esophagitis , North Carolina School , Chapel Hill ,

Dr. Maurizio Fava of Massachusetts General Hospital to Serve as Principal Investigator for PT00114 Clinical Trial

Share:
Clinical Trials of First-in-Class Peptide to Commence in 1H 2021
NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) Protagenic Therapeutics, Inc. (OTCQB:PTIX) announced today that Dr. Maurizio Fava, Psychiatrist-in-Chief at Massachusetts General Hospital (MGH), and Director of the Division of Clinical Research of the MGH Research Institute, will serve as the principal investigator in its upcoming clinical trial, a Phase 1/2a basket study designed to test PT00114 in healthy volunteers and patients with PTSD, Anxiety and Depression. PT00114 – Protagenic s lead drug compound – is known scientifically as teneurin C-terminal associated peptide (TCAP), a naturally occurring peptide responsible for regulation of stress response in the brain. PT00114 is a first-in-class compound, and has demonstrated compelling efficacy potential with a strong safety profile in extensive preclinical models. ....

United States , Noah Brown , Garo Armen , Exchange Commission , Protagenic Therapeutics Inc , Division Of Clinical Research , Research Institute , Senior Public Affairs Media Relations , Clinical Trials , First In Class Peptide , Maurizio Fava , Massachusetts General Hospital , Clinical Research , Post Traumatic Stress Disorder , Major Depressive Disorder , Generalized Anxiety Disorder , Executive Chairman , Protagenic Therapeutics , Protagenic Therapeutic , Risk Factors , Annual Report , Neuroendocrinol April , ஒன்றுபட்டது மாநிலங்களில் , நோவா பழுப்பு , கரோ ஆயுதங்கள் , பரிமாற்றம் தரகு ,